Biosimilar Expansion Fresenius Kabi is actively developing biosimilars in autoimmune diseases and oncology, with ongoing Vedolizumab and Rituximab programs and regulatory activity in the US and EU, signaling opportunities to partner on supply, manufacturing capacity, and distribution for biosimilar portfolios.

MedTech and IV Solutions A broad MedTech portfolio including infusion pumps, cell and gene therapy devices, disposables, and blood collection bags positions the company for cross-sell of complementary devices, disposables, and services to hospitals and blood banks seeking integrated care workflows.

Global Access Footprint With operations in over 100 countries and a focus on lifesaving medicines, Fresenius Kabi offers a wide international footprint for market expansion, localization partnerships, and supply chain collaborations to support rapid access programs and global tender opportunities.

Future Growth Strategy The #FutureFresenius initiative emphasizes developing and commercializing new therapies and technologies, creating opening for co-development, white‑labeling, and strategic partnerships across biosimilars, medical nutrition, and infusion therapies.

Recall and Quality Vigilance Recent recalls and safety notices underscore the importance of quality and risk management capabilities; this creates opportunities to offer remediation services, quality systems optimization, and serialization/traceability solutions to ensure patient safety and regulatory compliance.